ResultsIQ › Latest results › Sahajanand Medical Technologies Limited
Sahajanand Medical Technologies Limited (SMT) quarterly results
NSE: SMT · BSE: 545001
Sahajanand Medical Technologies Limited Q2 FY27 results
As filed: Revenue ₹373 cr, EBITDA ₹65.6 cr, PAT ₹26.5 cr, EBITDA margin 17.6%.
Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹373 cr). Scored once a year-earlier consolidated quarter exists.
AI summary: Earnings call, Q2 FY27
Earnings call of 5 Nov 2026, summarised by AI from the filing.
Structural heart grew about 40% in Q2 and ROW 37% in H1, now the largest region at 40% of revenue.
Key takeaways
- Growth mix Structural heart grew about 40% in Q2 and ROW 37% in H1, now the largest region at 40% of revenue.
- Operating leverage Employee cost fell to 27.1% of revenue from 28.8% and other expenses to 29.7% from 31.5%, lifting EBITDA margin.
- Gross margin H1 gross margin 74.3% vs 76%, down about 170 bps, about 150 bps from faster-growing lower-margin traded products.
Sahajanand Medical Technologies Limited earnings call summary
Sahajanand Medical Technologies Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.
About Sahajanand Medical Technologies Limited
Sahajanand Medical Technologies develops, manufactures and distributes vascular intervention and structural heart medical devices, including coronary stents, catheters, TAVI devices and occluders.
What Sahajanand Medical Technologies Limited does
The company develops, manufactures and distributes devices used in vascular intervention and structural-heart procedures. Its portfolio covers coronary stents and catheters, TAVI devices, occluders, renal stents, peripheral drug-coated balloons and traded products. It is an R&D-driven company engaged in the development of Class III and Class C/D medical devices, with an emphasis on Vascular Intervention (VI) and Structural Heart (SH). It operates three manufacturing facilities, two in India and one in Thailand.
How it makes money
- Revenue mix in FY2026: VI devices 61.14%, SH devices 16.77%; others 22.09%.
- Geographic mix in FY2026: India 26.13%; Europe 38.66%; rest of world 35.21%.
- Supraflex Cruz alone contributed 37.17% of FY2026 revenue.
- Products are marketed under its own brand.
Customers and markets
- The company marketed products in 77 countries in FY2026 through direct, hybrid and distributor-led channels.
- In India, through its hybrid model, it caters to large hospitals, including Narayana Hrudayalaya Limited.
- In Europe, it has direct operations in major markets such as Germany, Spain, France and UK; in certain other regions, such as Italy, it uses distributor-led models.
- Top 10 distributors contributed 15.71% of FY2026 revenue.
- Top 10 suppliers represented 59.15% of FY2026 purchases.
Plants and capacity
- India (two facilities): Stents, catheters, TAVI devices and occluders, capacity Stents 9,00,000; catheters 11,40,000; TAVI 9,000; occluders 42,000 (annual capacity) (FY2026)
- Thailand: Manufacturing facility
- Telangana: Stents and balloons (SMT Cardiovascular Private Limited, wholly owned subsidiary) (Operational since October 2022)
Segments
- Vascular Intervention (VI) devices: 61.14% of revenue, FY2026
- Structural Heart (SH) devices: 16.77% of revenue, FY2026
- Others: 22.09% of revenue, FY2026
Key facts
- Founded: Founded by Dhirajlal Kotadia in 2001 (Crisil says the SMTL group was founded in 1993; SMTL incorporated in 1998)
- Headquarters: Sahajanand Estate, Wakharia Wadi, Nr. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat 395004
- Promoter group: Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen, Shree Hari Trust
- Promoter holding: 40.92% pre-issue; 36.2% post-issue (October 2026 IPO)
- Credit rating: Crisil A-/Stable (long term, upgraded from Crisil BBB+/Stable); Crisil A2+ (short term, upgraded from Crisil A2) (November 03, 2026)
- Operating revenue: Rs 1,214 crore in fiscal 2026 against Rs 1,032 crore in fiscal 2025 (FY2026)
- Operating margin: 13.14% in fiscal 2026, 12.87% in fiscal 2025, 12.76% in fiscal 2024 (FY2026)
- IPO: Offer for sale of up to 1,38,22,116 equity shares at Rs 327-344 per share; no fresh issue (October 2026)
What the company says sets it apart
- The company says it reported an Indian drug-eluting-stent market share of nearly 25% by sales volume in FY2026, based on the industry report included in the RHP.
- The company says it was the first company in the world to receive a CE certification for a DES with a biodegradable polymer-based paclitaxel-eluting stent (Infinnium).
- The company says it has 119 granted patents and a sizeable pipeline of patent applications.
- The company says it has a proprietary cardiovascular-device platform with a broad clinical portfolio.
- The company says it has established manufacturing and regulatory infrastructure across India and Thailand.
The company's own claims, as stated in its filings and website.
AI-written from 6 public sources; every line links its source on the page.